Four independent studies demonstrate that rovalpituzumab tesirine for small-cell lung cancer (SCLC) is not effective against SCLC, casting a pall over the future of the therapy and closing a door that seemed opened four years ago when the first study on the therapy was published.
Click here for original story, Four independent studies show rovalpituzumab tesirine ineffective against small cell lung cancer
Source: ScienceDaily